DisposalHealthcare - Pharma - Biotech
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12
10/11/2026 08:35
AMFImmediate publication
Berlin, Germany, November 10, 2026, 8.30 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, publishes further details regarding the exclusive negotiation agreement and non-binding term sheet signed with TMS Co., Ltd.…
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12
Berlin, Germany, November 10, 2026, 8.30 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech-company with clinical assets for brain cancer and eye diseases, publishes further details regarding the exclusive negotiation agreement and non-binding term sheet signed with TMS Co., Ltd. on October 29, 2026.
Binding and non-binding terms
- The exclusive negotiation period of 6 months and the non-refundable exclusivity fee of €150,000 are binding. The period may be extended by up to three months against a nonrefundable payment of €50,000 per month.
- The economic terms are negotiated as basis for the further discussions for a definitive license agreement; these terms are non-binding and may differ in a definitive agreement; there is no assurance that a definitive agreement will be concluded. A definitive agreement would only become effective once TMS’ Japanese Subsidiary has secured enough funding for the GLORIA Trial to be restarted.
Financial terms
- Near term payments to TME Pharma of approximately € 10 million are conditional to signing of this definite agreement; approximately half is expected to come in cash and approximately half in equity in the Subsidiary with up to 20% shareholding. By becoming a shareholder in the Subsidiary, the potential long term value (in case of successful results from the GLORIA Trial) for TME Pharma shareholders, will increase.
- Revenue potential from milestone payments is more than €100 million, thereof approximately €37 million in regulatory milestones through approval (with the potential for the earliest first payment to be received after 2 years), the remainder being milestones linked to sales. Tiered royalties on net sales (8-10%) and a share of potential sublicensing revenues would be further in the future. All milestones and royalties depend on clinical, regulatory and commercial success and may never be received. Investors can use a risk-adjusted valuation model to calculate potential value of the potential agreement, weighing future revenue streams against the risk of failing to achieve the ultimate goals.
Market size and sales estimate
TME estimates that the market for first-line treatment of newly diagnosed glioblastoma in the US and the EU-27 could be worth approximately €3 billion per year at the time NOX-A12 is launched, growing to approximately €4 billion per year by 20461. This estimate assumes a twelve-month course of treatment priced in line with atezolizumab, an approved cancer checkpoint antibody, when used in combination with bevacizumab2. Approximately 54% of newly diagnosed patients have chemotherapy 1 TME estimates based on Eurostat and US Census Bureau population projections; incidence based on Crocetti et al., European Journal of Cancer, 2012 and Ostrom et al., Neuro-Oncology, 2019 2 Pricing sources: US: Medicare Payment Limit; UK: NICE; Germany: G-BA Federal Joint Committee; France: HAS Avis Economique; Italy Gazzetta Ufficiale; Spain Ministry of Health/National Health System. Accessed Q1 2026 refractory (MGMT-unmethylated) tumors3 for whom current treatments are least effective; this is the population studied in the GLORIA trial. Assuming successful clinical development and regulatory approval of NOX-A12, which are uncertain, and a market share of approximately half of the chemotherapy refractory patients, TME estimates annual sales of approximately €1 billion around 2040. For its internal risk-adjusted product valuation of this product, TME Pharma applies industrystandard attrition rates for oncology products4.